Nocturne boardroom ilikuwa kwenye ghorofa ya juu yenye kioo kisichoonyesha ndani. Adrian Vale alikuwa amekaa mwisho wa meza. Maira upande mwingine, si karibu naye. Zawadi aliingia na disclosure order ya tribunal. Leila alikuwa technical observer kwa records zinazohusiana na formulation, si board privilege ambayo regulator angeamua.
Emergency board meeting ilikuwa imeitishwa kwa sababu interim order ilitaka technical specs na reporting records zitolewe kwa Board. Adrian alitaka company itoe minimum inayohitajika. Maira alitaka minutes ambazo tayari zimeingia kwenye scope zisitumike kuficha financial decisions.
“Tutatoa clinical packet,” Adrian alisema. “Commercial projections hazihusiani na safety.”
Maira akafungua folder. “Zinahusiana kama board ilipewa warning na ikaendelea ku-budget expansion.”
“Finance haikuamua clinical materiality.”
“Sijasema hivyo.”
Hapo ndipo ufa ulikuwa. Maira hakujaribu kuwa scientist. Alikuwa akitenganisha kile alichojua na kile ambacho hakujua.
Zawadi akaomba minutes za meeting ya wiki tano kabla expansion. Board secretary akaleta certified copy. Agenda item moja ilikuwa “formulation update and retention forecast.”
Leila alisoma technical summary tu. Safety signal ilikuwa imetajwa kama “under study, non-material pending confirmation.” Chini yake, financial projection ilikadiria retention ya care plans kwa miezi inayofuata.
Maira akaonyesha spreadsheet appendix. “Projection hii inategemea refill frequency.”
Adrian akasema, “Refill frequency ilikuwa proxy ya clinical engagement.”
“Pia ilikuwa revenue input,” Maira akajibu. “Hayo mambo mawili yanaweza kuwa kweli kwa wakati mmoja.”
Leila aliona line ya model: higher repeat engagement → increased lifetime plan adherence. Hakujua model hiyo ilimaanisha intent ya kuongeza episodes. Haikusema hivyo. Lakini ilionyesha kampuni ilitarajia thamani ya kifedha kutoka kwa patients kubaki kwenye plan kwa muda mrefu.
Zawadi akauliza, “Board iliona warning memo kamili?”
Maira akasema, “Sio mimi. Tuliona summary.”
Adrian akasema, “Clinical committee iliona full signal.”
“Na ilii-classify non-material?”
“Pending study, ndiyo.”
“Minutes za committee?”
Counsel akapinga kwa privilege na ongoing internal review. Zawadi akaonyesha tribunal order. Scope ya regulatory safety records ilikuwa explicit.
Wakati counsel akibishana, Maira aliomba board secretary aweke tofauti kati ya documents ambazo finance team ilipokea na ambazo clinical committee ilishikilia. Folder mbili zikajengwa papo hapo. Finance folder ilikuwa na retention forecasts, expansion costs na board summary. Clinical folder ilikuwa na raw signal charts, caution wording na testing recommendations.
Zawadi akasema, “Hii distinction iende kwenye index. Tusije tukasema CFO aliona chart ambayo hakuiona.”
Maira akakubali. Adrian akasema kwa uchovu, “Lakini board ilijua kuna study.”
“Ndiyo,” Maira akasema. “Ilijua kuna study. Haikujua recommendation ilikuwa reassess before broad scale.”
Leila aliona kwa nini precision ilikuwa muhimu hata kwa mtu ambaye angeweza kuwa implicated. Truth ambayo inapanuka kupita record huwa zawadi kwa defense.
Baada ya dakika ishirini za legal argument, certified minutes zikawekwa mezani.
Hapo chronology ikawa wazi zaidi. Clinical team iliona repeated-exposure sensitization signal. Haikuita confirmed harm. Recommendation ilikuwa monitor, limit claims, and reassess before broad scale. Board summary ilipunguza hilo kuwa “non-material pending study.” Expansion haikusimama.
Leila alisoma line mara mbili. “Reassess before broad scale” haikuonekana kwenye board summary.
Adrian akasema, “Technical committee haikutoa stop order.”
“Hilo ni kweli,” Zawadi alisema. “Na pia full caution wording haikufika kwenye summary. Vyote vitaingia record.”
Maira akafunga macho kwa sekunde. “Nilipiga kura expansion budget kwa summary hiyo.”
Adrian akamgeukia. “Usijifanye hujui risk ipo kwenye healthcare.”
“Sijifanyi. Nasema sikupewa wording kamili.”
“Na sasa unataka kuokoa jina lako kwa kutoa company records?”
Maira akasimama. “Nataka kutenganisha kile nilichojua na kile ambacho sikujua. Hicho ndicho mnachotufundisha kila siku kuhusu disclosure, sivyo?”
Chumba kikawa kimya.
Zawadi hakumpongeza. Aliuliza procedure. “Board inaweza kupiga kura release ya minutes zilizo ndani ya order bila litigation kuhusu kila page?”
Board secretary akasema ndiyo.
Adrian alipiga kura dhidi. Directors wawili wakasita. Maira akapiga kura kutoa records kwa regulator chini ya confidentiality limits na public safety summary baadaye. Director mmoja akafuata. Kura ikapita kwa margin ndogo.
Kabla vote, Adrian alimwangalia Maira moja kwa moja. “Ukitoa minutes hizi, competitors wataona weakness na patients wataogopa.”
Maira akasema, “Patients tayari wanaogopa. Swali ni kama tunawapa reason ya kuamini correction inaweza kutokea bila founder kuruhusu.”
Director mmoja akauliza kama release ingeweza kuishia Board tu. Zawadi akasema ndiyo; public summary ingekuwa separate na redactions zinazolinda patient privacy na legitimate trade secrets ambazo hazihitajiki kwa safety. Hiyo ilifanya director huyo abadili kura.
Huo haukuwa ushindi wa Leila. Hakupiga kura. Haukuwa redemption kamili ya Maira pia. Alikuwa CFO wa system iliyofaidika na retention. Lakini internal unity ya Nocturne ilivunjika rasmi.
Baada ya vote, Maira alisaini disclosure statement yake mwenyewe. Aliweka wazi kwamba alijua retention model na revenue sensitivity kwa refill frequency; hakujua clinical committee ilikuwa imeandika “reassess before broad scale” mpaka full minutes zilipotolewa. Hakujaribu kujisafisha zaidi ya hapo.
“Utaamini?” alimwuliza Leila.
“Si kazi yangu kukuamini. Record itaonyesha unachoweza kuthibitisha.”
Maira akatabasamu bila furaha. “Sasa nimeanza kuelewa kwa nini Zawadi anakupenda.”
“Hanipendi.”
Kwa mara ya kwanza siku hiyo, Maira akacheka.
Records ziliwekwa kwenye encrypted transfer kwa Board. Zawadi akathibitisha hash na receipt. Leila akapata only technical extracts alizohitaji.
Kwenye expansion deck, slide moja ilionyesha map ya clinics mpya. Chini yake kulikuwa na promise kwa investors: “lifetime adherence architecture” kupitia integrated care identity, refill continuity na account retention.
Tarehe ya deck ilikuwa baada ya clinical warning memo.
Board secretary pia alitoa version history ya expansion deck. Phrase “lifetime adherence architecture” haikuwa typo ya draft ya mwisho; ilikuwa imeongezwa baada ya revenue model kukubaliwa na ikabaki kwenye version iliyowasilishwa kwa investors. Leila hakuiita proof ya intent ya kuwafanya wagonjwa waendelee kuumwa. Aliiweka kama evidence kwamba commercial strategy ilithamini continuity ya muda mrefu wakati safety signal ilikuwa bado under study.
Maira alisaini acknowledgment ya version history. Adrian alikataa ku-comment zaidi bila counsel. Hilo nalo likaingia record bila tafsiri ya ziada.
Expansion ilikuwa imeahidi lifetime adherence baada ya warning.